SEC Comment Letter 0000000000-23-007088 to Enveric Biosciences, Inc. (ENVB)

Enveric Biosciences, Inc.
Date: July 5, 2023 · CIK: 0000890821 · Accession: 0000000000-23-007088

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-38286

Date

July 5, 2023

Author

Kevin Coveney

Form

UPLOAD

Company

Enveric Biosciences, Inc.

Letter

United States securities and exchange commission logo July 5, 2023 Kevin Coveney Chief Financial Officer Enveric Biosciences, Inc. 4851 Tamiami Trail N, Suite 200 Naples, Florida 34103 Re:Enveric Biosciences, Inc. Form 10-K for Fiscal Year Ended December 31, 2022 Filed March 31, 2023 File No. 001-38286 Dear Kevin Coveney: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
July 5, 2023
Kevin Coveney
Chief Financial Officer
Enveric Biosciences, Inc.
4851 Tamiami Trail N, Suite 200
Naples, Florida 34103
Re:Enveric Biosciences, Inc.
Form 10-K for Fiscal Year Ended December 31, 2022
Filed March 31, 2023
File No. 001-38286
Dear Kevin Coveney:
            We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io